Source link : https://www.newshealth.biz/health-news/nemolizumab-reassures-in-long-term-atopic-dermatitis-study/
AMSTERDAM — The monoclonal antibody nemolizumab offers long-term efficacy and safety, as well as quality-of-life benefits, in the management of adolescents and adults with moderate to severe atopic dermatitis (AD), revealed an interim analysis of the ARCADIA open-label extension study. The research was presented at the European Academy of Dermatology and Venereology (EADV) 2024 Congress […]
Author : News Health
Publish date : 2024-10-21 10:28:33
Copyright for syndicated content belongs to the linked Source.
